163 related articles for article (PubMed ID: 15908423)
1. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells.
Arva NC; Gopen TR; Talbott KE; Campbell LE; Chicas A; White DE; Bond GL; Levine AJ; Bargonetti J
J Biol Chem; 2005 Jul; 280(29):26776-87. PubMed ID: 15908423
[TBL] [Abstract][Full Text] [Related]
2. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.
Rosso M; Polotskaia A; Bargonetti J
Oncotarget; 2015 Oct; 6(33):34573-91. PubMed ID: 26416444
[TBL] [Abstract][Full Text] [Related]
3. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.
Arva NC; Talbott KE; Okoro DR; Brekman A; Qiu WG; Bargonetti J
Ethn Dis; 2008; 18(2 Suppl 2):S2-1-8. PubMed ID: 18646312
[TBL] [Abstract][Full Text] [Related]
5. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification.
Knights CD; Liu Y; Appella E; Kulesz-Martin M
J Biol Chem; 2003 Dec; 278(52):52890-900. PubMed ID: 14555661
[TBL] [Abstract][Full Text] [Related]
6. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription.
White DE; Talbott KE; Arva NC; Bargonetti J
Cancer Res; 2006 Apr; 66(7):3463-70. PubMed ID: 16585169
[TBL] [Abstract][Full Text] [Related]
7. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.
Hu W; Feng Z; Ma L; Wagner J; Rice JJ; Stolovitzky G; Levine AJ
Cancer Res; 2007 Mar; 67(6):2757-65. PubMed ID: 17363597
[TBL] [Abstract][Full Text] [Related]
8. A possible role of p73 on the modulation of p53 level through MDM2.
Wang XQ; Ongkeko WM; Lau AW; Leung KM; Poon RY
Cancer Res; 2001 Feb; 61(4):1598-603. PubMed ID: 11245471
[TBL] [Abstract][Full Text] [Related]
9. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein.
Dobbelstein M; Wienzek S; König C; Roth J
Oncogene; 1999 Mar; 18(12):2101-6. PubMed ID: 10321734
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Arriola EL; Lopez AR; Chresta CM
Oncogene; 1999 Jan; 18(4):1081-91. PubMed ID: 10023685
[TBL] [Abstract][Full Text] [Related]
12. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells.
Galatin PS; Abraham DJ
J Med Chem; 2004 Aug; 47(17):4163-5. PubMed ID: 15293988
[TBL] [Abstract][Full Text] [Related]
13. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.
Stommel JM; Wahl GM
EMBO J; 2004 Apr; 23(7):1547-56. PubMed ID: 15029243
[TBL] [Abstract][Full Text] [Related]
14. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
15. MDM2 and MDMX bind and stabilize the p53-related protein p73.
Ongkeko WM; Wang XQ; Siu WY; Lau AW; Yamashita K; Harris AL; Cox LS; Poon RY
Curr Biol; 1999 Jul 29-Aug 12; 9(15):829-32. PubMed ID: 10469568
[TBL] [Abstract][Full Text] [Related]
16. Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2.
O'Hagan HM; Ljungman M
Oncogene; 2004 Jul; 23(32):5505-12. PubMed ID: 15094782
[TBL] [Abstract][Full Text] [Related]
17. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.
Mayo LD; Seo YR; Jackson MW; Smith ML; Rivera Guzman J; Korgaonkar CK; Donner DB
J Biol Chem; 2005 Jul; 280(28):25953-9. PubMed ID: 15843377
[TBL] [Abstract][Full Text] [Related]
19. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
Wunderlich M; Berberich SJ
Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates.
Shiraishi T; Nielsen PE
Nucleic Acids Res; 2004; 32(16):4893-902. PubMed ID: 15371552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
